Teva Takes A Further Hit On Value Of Actavis
Teva has registered a further impairment of almost $500m, largely linked to the value of assets acquired when it took over Actavis in 2016. Meanwhile, sales slid by 15% to $4.3bn in the first quarter.
You may also be interested in...
Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.
Teva has received FDA approval for the first US generic naloxone nasal spray after a 30-month stay linked to ongoing patent litigation expired. Launch plans have not yet been revealed. Meanwhile, the Israeli firm has also introduced the first generic version of VESIcare in the US.